Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Omeros Corporation

< Previous 1 2 3 Next >
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Second Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
From Omeros Corporation
Via Business Wire
Tickers OMER
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports First Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Third Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Second Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.